Interferon beta 1a inhalation - Synairgen

Drug Profile

Interferon beta 1a inhalation - Synairgen

Alternative Names: Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator University of Southampton
  • Developer AstraZeneca; Synairgen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease
  • Preclinical Influenza virus infections

Most Recent Events

  • 14 Oct 2016 AstraZeneca terminates a phase IIa trial in Asthma (Prevention) in Australia, Argentina, France, Spain, the UK, South Korea and Colombia
  • 14 Sep 2015 Phase-II clinical trials in Asthma in Argentina and Australia (Inhalation) after September 2015 (NCT02491684)
  • 14 Sep 2015 Phase-II clinical trials in Asthma in France (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top